Wall Street Zen upgraded shares of AgomAb Therapeutics (NASDAQ:AGMB – Free Report) to a hold rating in a research report released on Tuesday morning.
AgomAb Therapeutics Stock Performance
Shares of NASDAQ AGMB opened at $15.15 on Tuesday. AgomAb Therapeutics has a 52 week low of $12.66 and a 52 week high of $16.65.
About AgomAb Therapeutics
AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.
AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.
Read More
- Five stocks we like better than AgomAb Therapeutics
- Energy Security Is Now National Security – Positioning Is Happening Now
- 1968. 1980. 2020. Here’s the pattern…
- Your Bank Account Is No Longer Safe
- Trump’s AI Secret: 100X Faster Than Nvidia
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for AgomAb Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgomAb Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
